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A B S T R A C T   
The dominant sex hormone testosterone is mainly metabolized by liver enzymes belonging to the uridine- 
diphospho (UDP) glucuronosyltransferase (UGT) family. These enzymes are the main phase II enzymes, and 
they have an important role in the detoxification of endogenous and exogenous compounds in humans. The aim 
of the present study was to improve the understanding of the binding properties of UGT2B17. A homology 
modelling procedure was used to generate models of the UGT2B17 enzyme based on templates with known 
crystal structures. Molecular docking of inhibitors was performed to gain further insights in the interactions 
between ligand and binding site, and to determine which of the models had the best accuracy. ROC curves were 
made to evaluate the ability of the models to differentiate between binders (inhibitors) and non-binders (decoys). 
When comparing the four models, which were based on four different crystal structures, the model based on the 
4AMG crystal structure was the most accurate in distinguishing between true binders and non-binders. Inves-
tigating pharmacological UGT2B17 inhibition may provide novel treatment for patients with low testosterone 
levels. Such treatment may elevate endogenous testosterone levels and provide a more predictable increase in 
serum concentrations rather than un-physiological elevation of serum levels through direct treatment with 
testosterone, and this could be favorable both for giving a predictable treatment regime with reduced chances of 
serious adverse effects. The present study may serve as a tool in the search for novel drugs aiming for increasing 
testosterone levels.   
1. Introduction 
Testosterone is the dominant male sex hormone, and it plays a key 
role in the male pubertal development of testes and prostate, as well as 
promoting masculine characteristics such as increased muscle and bone 
mass, height, and the growth of body hair. In males, testosterone is 
produced in testicular Leydig cells, while in females, testosterone is 
produced in the ovaries, giving serum concentrations of between 5 and 
10% of male levels. Through adolescence testosterone helps maintain 
the libido, sperm production, muscle and bone mass, and male hair 
pattern. Male hypogonadism is a clinical condition characterized by low 
serum testosterone levels in combination with a variety of symptoms 
and signs such as reduced libido and vitality, reduced muscle mass, 
increased fat mass and depression.30 
Testosterone is mainly metabolized by liver enzymes belonging to 
the uridine-diphospho (UDP) glucuronosyltransferase (UGT) family. 
UGTs are the main phase II enzymes, and they have an important role in 
the detoxification of endogenous and exogenous compounds in 
humans.19 UGTs catalyze the transfer of a glucuronyl group to a lipo-
philic substrate following the phase I reaction, forming a more water 
soluble and thus more rapidly excreted compound. The glucuronyl 
group is transferred from the uridine-diphosphoglucuronic acid 
(UDPGA) co-substrate.14 
There are 22 known UGTs from families UGT1-3 and UGT8 (Meech 
et al. Physiological Reviews, 2019, 99, 1153–1222), and these are 
divided into families UGT1-3. Androgens can be metabolized by three 
different isoforms of the UGT2 family, UGT2B7, UGT2B15 and 
UGT2B17, with the latter being the most efficient. UGT2B17 also has the 
ability to conjugate dihydrotestosterone (DHT).19,25,11 
UGTs are composed of two functional domains, a variable N-terminal 
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(NT) domain (residues 1–265) and a highly conserved C-terminal (CT) 
domain (residues 266–530), with a catalytic site in the cleft between the 
two domains. The NT domain contains a signal peptide that mediates the 
integration into the ER-lumen, the aglycone binding site, and a mem-
brane interacting region. The CT domain contains most of the UDPGA 
cofactor binding site and a transmembrane helix near the carboxy- 
terminus with a cytosolic tail. The enzyme is predicted to form dimers 
in endoplasmic reticulum membranes, this may have an effect on 
function and acceptor ligand specificity.19,25,20 
UGT inhibition is important to investigate when developing novel 
potential drugs. Inhibition of drug metabolizing enzymes is a major 
mechanism in drug-drug interactions, and a number of cases of drug- 
drug interactions via inhibition of UDP-glucuronosyltranseferases 
(UGTs) have been reported (https://dmd.aspetjournals.org/content/ 
43/6/812). Among approximately 500 known inhibitors are atazana-




20) lapatinib, pazopanib, regorafenib and sorafenib (https://www.sci 
encedirect.com/science/article/abs/pii/S0006295219303065). 
The aim of the present study was to improve the understanding of the 
binding properties of UGT2B17, thereby making it possible to develop 
selective inhibitors of the enzyme. Inhibitors of UGT2B17 could help 
maintain normal testosterone levels in patients with clinical conditions 
that reduce testosterone production. The models presented in this study 
may be used in drug development studies in order to treat male hypo-
gonadism and other conditions with low testosterone, and coordinates 
are available as supplementary material. 
A homology modelling procedure was used to generate models of the 
UGT2B17 enzyme based on templates with known crystal structures. 
Molecular docking of inhibitors on the models was performed to gain 
further insights in the interactions between ligand and binding site, and 
to determine which of the models had the best accuracy. 
2. Materials and methods 
2.1. Software and databases 
The Molsoft Internal Coordinates Mechanics (ICM) (Version 3.8.7) 
program,2 which gives a general modelling and structure prediction 
framework for many different tasks of structural biology and rational 
drug design, was used to build homology models of the enzymes and 
docking of ligands and decoys in this study. The ICM method has been 
extensively validated in bioinformatics and drug discovery pro-
jects.13,7,16 The Protein Data Bank (PDB),5 which is a data bank of 
experimentally determined 3D structures of biological macromolecules, 
was used to retrieve templates. The Universal Protein Resource Knowl-
edgebase (UniProtKB),4 which is a comprehensive resource for protein 
sequence and functional information with detailed annotations, was to 
used find amino acid sequences for target and template proteins. The 
Basic Logical Alignment Search Tool (Blast),3 which is a search tool that 
finds regions of similarity between biological sequences, from the Na-
tional Center for Biotechnology Information sequence database, was 
used to find potential templates with sequence homology of known 3D 
structures. The Structural Analysis and Verification Server (SAVES) v5.0 
(https://servicesn.mbi.ucla.edu/SAVES/), which is a part of web ser-
vices provided by the Molecular Biology Institute at the University of 
California, Los Angeles, was used to analyze and validate protein 
structures. ChEMBL,10 which is a database of bioactive compounds with 
drug-like properties, was used to search for compounds, targets and 
assays. DecoyFinder,8 which is a graphical tool designed to aid molecular 
docking programs by providing challenging decoys for a given group of 
active ligands, was used to retrieve decoys with similar physiochemical 
properties assumed to be inactive for the UGT2B17 enzyme. The soft-
ware acquires the decoys directly from the ZINC compounds database.8 
3. Homology modelling 
3.1. Template identification 
The amino acid sequence of human UGT2B17 was retrieved from the 
UniProtKB database,4 with accession number O75795. Close homo-
logues of the human UGT2B17 were found using the Blast search tool3 
for a sequence similarity search with the target sequence as query. A 
standard protein–protein Blast was performed on the 530 residues of the 
human UGT2B17 amino acid sequence, resulting in a list of potential 
templates with available crystal structures. 
Most of the potential templates were UGTs with a sequence identity 
of about 20% to UGT2B17, but one partial structure of an UGT had a 
high sequence identity to UGT2B17. The partial structure (PDB id: 
2O6L)20 consisted of the CT domain of the closely related enzyme 
human UDP-glucuronosyltransferase 2B7 (UGT2B7), and had a 
sequence identity of 82% with the query sequence. The CT domain 
included most of the residues that make up the binding site of the 
UDPGA cofactor. Consequently, this made the crystal structure useful as 
a template for a model of the CT domain of target, but also as a part of a 
multi template model where two templates are combined in the 
modelling process. The crystal structure of UGT2B7 was crystallized as a 
dimer, with chains designated A and B. Since chain B lacked some res-
idues located close to the binding site, chain A was chosen for modelling. 
Because of the high sequence identity of UGT2B7 with the target, 
combined with the low sequence identity in most of the other potential 
templates, a multiple template modelling procedure was the best option 
for an acceptable full length model of both domains. The rationale for 
building a model with both domains was based on studies indicating 
interactions between the co-factor UDPGA and residues in the NT 
domain.25,20 In addition, a partial model of the CT domain of the enzyme 
was built based on UGT2B7 alone. This model could lack some residues 
of importance to UDPGA binding, but would have higher sequence 
identity. 
To model both domains of the target protein there was a need for 
templates with acceptable sequence identity to the NT, in addition to the 
partial structure of UGT2B7. A delta-Blast algorithm of the first 284 
residues from the NT domain of target was performed, resulting in a long 
list of potential templates. UGTs where marked for next iteration, and 
followed by a psi-Blast algorithm. This resulted in a new list of 48 po-
tential templates. The templates obtained from the Blast search tool 
where shortlisted and investigated further based on: (1) conserved 
UDPGA binding site, (2) sequence identity, (3) query cover, (4) resolu-
tion, and (5) expectation-value. All the templates considered had most of 
the UDPGA binding site conserved, but ultimately this region, which was 
focus of the present study, was modelled from the UGT2B7 template. 
The query cover of all templates were all over 80%, except from the 
partial structure with 31% query cover. The resolution of the chosen 
templates ranged from 1.7 Å to 2.59 Å. The expectation value (e-value) 
is a parameter describing the number of different alignments expected to 
occur by chance in a database search, the lower the e-value, the better 
the alignment. Proteins with an e-value above 0.0001 were excluded. 
Thus, the following crystal structures were chosen as templates for ho-
mology modelling, PDB id: 3WAD,21 4AMG,9 4M8328 and 2O6L,20 as 
shown in Table 1. The sequence identities between the target and 
Table 1 







3WAD Glycosyltransferase VinC 20% 2.00 Å 21 
4AMG Glycosyltransferase SnogD 22% 2.59 Å 9 




82% 1.80 Å 20  
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template sequences are much lower than the requirement (>or = 30%) 
for a structure that can be used as a template for homology modeling, 
and the sequence similarities are 25.6% (3WAD), 24.8% (4AMG), 27.3% 
(4 M83) and 84.4% (2O6L). The values for 3WAD, 4AMD and 4 M83 are 
below what is regarded as acceptable in homology modeling, but the 
since the binding site of interest was located in the CT-region where the 
2O6L template was used, the sequence identity in the region of interest 
was acceptable. 
3.2. Sequence alignment 
The templates selected for homology modelling were aligned with 
the sequence of UGT2B17 using the alignment tool in the ICM software. 
The sequence of 2O6L20 needed no adjustment because of the high 
sequence identity. The other templates had relatively low homology 
with target, and needed manual adjustment. By using a multiple 
sequence alignment of the templates combined with several other 
human UGTs, a basis for further adjustment was built, as shown in 
Figure 1. 
Site-directed mutagenesis studies of human UGTs25,26,29,23 where 
used to guide the alignment process. Residues H35 and D152 act as a 
catalytic dyad in the catalytic reaction initiating the glucuronidation 
mechanism of the enzyme. Residues R49 and H51 have a role in function 
and structural integrity required for optimal catalytic activity, but are 
not directly involved in substrate binding. The residue F90 forms aro-
matic ring stacking interactions with phenolic substrates. The residue 
S121 is required for the ability to conjugate C19 steroids at the 3α-OH 
position, thereby being involved in steroid specificity. The residues S309 
and R339, in 
addition to many residues in the region 357–400 are involved in 
UDPGA binding, and forms the binding pocket.25,26,29,23 The adjusted 
sequence alignments shown in Figures 2-5 were used to build the models 
of UGT2B17. 
3.3. Model building 
One partial model of the CT domain, and three full length models of 
both domains of UGT2B17 were built based on four different crystal 
structures. All templates belong to the UGT family and were the most 
suitable candidates with regards to the criteria for template 
identification.  
1. Bacterial glycosyltransferase VinC in complex with magnesium ion 
PDB id: 3WAD,21 resolution 2.0 Å, chain A, length 398 residues  
2. Bacterial glycosyltransferase SnogD PDB id: 4AMG,9 resolution 2.59 
Å, chain A, length 362 residues 
Figure 1. Multiple sequence alignment of several homologous UGTs and the chosen templates. Areas with dark green colour indicates fully conserved residues, 
yellow colour indicates semi conserved. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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Figure 2. Sequence alignment for UGT2B17 and 3WAD used for homology modelling. Areas with green colour indicates conserved residues. Red annotation marks 
region for multiple templates. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
I. Trane et al.                                                                                                                                                                                                                                    
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Figure 3. Sequence alignment for UGT2B17 and 4AMG used for homology modelling. Areas with green colour indicates conserved residues. Red annotation marks 
region for multiple templates. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
I. Trane et al.                                                                                                                                                                                                                                    
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Figure 4. Sequence alignment for UGT2B17 and 4 M83 used for homology modelling. Areas with green colour indicates conserved residues. Red annotation marks 
region for multiple templates. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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Figure 5. Sequence alignment for UGT2B17 and 2O6L used for homology modelling. Areas with green colour indicates conserved residues. Red annotation indicates 
the UDPGA binding region. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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3. Bacterial glycosyltransferase OleD in complex with Erythromycin A 
and UDP PDB id: 4M83,28 resolution 1.7 Å, chain A, length 393 
residues  
4. Human UDP glucuronosyltransferase 2B7 PDB id: 2O6L,20 resolution 
1.8 Å, chain A, length 162 residues 
The partial model and three complete initial models were made using 
the Homology macro in ICM. The Multi-Template Model Editor macro 
was used to improve the quality of the three GT based models by adding 
2O6L20 as a second template for their CT domain. Since the target 
sequence contained a signal peptide, a transmembrane region and a 
cytosolic tail not present in the GT templates, the excessive carboxy- and 
amino terminus tails generated by the modelling procedure were trim-
med of the models to avoid them interacting with the secondary 
structures. 
3.4. Model refinement 
The Refine Model macro2 of the ICM software was used to refine the 
built models, a full refinement and optimization of backbone, sidechains 
and loops were carried out. This refinement macro included (1) Monte 
Carlo fast simulations for sampling of the conformational space of side 
chains, (2) repeated annealing of the backbone with tethers, and (3) a 
second run of Monte Carlo fast simulations on the side chains. Each 
repetition of Monte-Carlo fast samples the conformational space of the 
molecule with the ICM global optimization procedure, which consists of 
a random move followed by a local energy minimization, and then a 
complete energy calculation. Based on the energy and temperature, the 
repetition is either accepted or rejected. 
3.5. Model validation 
The SAVES metaserver (https://servicesn.mbi.ucla.edu/SAVES/) 
was used to analyze and validate the built models. Of the different 
programs available in the metaserver, ProCheck17 and WhatCheck12 
were chosen for the validation. ProCheck investigates the stereo chem-
ical quality of a protein structure by analyzing the overall and residue- 
by-residue geometry, and the result of the analysis is represented by a 
Table 2 
UGT2B17 inhibitors.  
ID Structure Chemical composition CHEMBL ID PubMed ID IC50 (µM) Ki (µM) 
1 C29H34N7O CHEMBL941 96,642,944 0.8 0.4 
2 C30H18O10 CHEMBL63354 29,470,958 2.1 2.1 
3 C15H16O2 CHEMBL418971 23,948,605  19.9 
4 C21H3O CHEMBL376840 17,474,732  21.8 
5 C9H12N2O12P2 CHEMBL130266 17,998,297  100.0 
6 C19H16O4 CHEMBL1464 25,393,417  166.8 
7 C21H22O4 CHEMBL139702 26,875,642 32.0  
8 C31H33N3O6S CHEMBL603 25,834,030 50.0  
9 C14H11Cl2NO2 CHEMBL139 19,643,121 65.0  
10 C13H17O2 CHEMBL521 19,643,121 1340.0   
Figure 6. Superimposition of UDPGA (yellow) binding site with 2O6L (pink) and 4 M83 (light blue) with UDP (orange). (For interpretation of the references to color 
in this figure legend, the reader is referred to the web version of this article.) 
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Ramachandran plot. WhatCheck did extensive checking of many stereo 
chemical parameters of the residues in the models. 
In order to identify structural differences between the models and 
their templates, the root-meansquare-deviation (RMSD) was also 
calculated by ICM for the CT domain and for the binding pocket. RMSD 
is a measure of the degree of similarity of two protein 3D structures, and 
it calculates the average distance between equivalent backbone Cα 
atoms by superimposing the models on their templates.18,16 
4. Molecular docking 
Molecular docking is a method used to predict protein ligand in-
teractions within a targeted binding site, and score their potential 
complementarity. Exploring these interactions are important for our 
understanding of how the protein function, and for the development of 
new drug molecules. Studies on the co-factor binding site of UGT2B17 
may provide insights on the formation of the ligand–protein complex, 
and the intermolecular forces deciding specificity and affinity of a 
ligand. The formation of a ligand–protein complex may lead to struc-
tural changes in both ligand and protein. Retrieving information about 
protein ligand interactions can assist in designing new inhibitors with a 
good fit in the binding pocket.22 
4.1. Inhibitors and decoys 
To validate the models ability to differentiate between inhibitors and 
decoys, a set of known inhibitors of UGT2B17 were retrieved from 
PubChem and ChEMBL, examining studies where the UDPGA binding 
site in UGT2B17, or UGTs in general had been investigated. 17 inhibitors 
with varying ability to inhibit UGT2B17 were identified, of these were 
10 selected based on known IC50 or Ki values, as shown in Table 2. 
Ideally, the docking would be performed with experimentally 
determined decoys for target, but none were available at time of this 
study. To acquire decoys, the known inhibitors were entered as tem-
plates into the Decoyfinder software.8 The DecoyFinder software finds 
molecules which have similar number of rotational bonds, HBA, HBD, 
logP value, and molecular weight, but are chemically different from the 
active ligands used as input. The software generated a set of 145 decoy 
substances with similar physiochemical properties as the inhibitors. The 
decoys were inserted into a chemical table with the inhibitors, giving a 
dataset of 155 substances ready for docking. 
4.2. Ligand and model preparation 
Inhibitors and decoys were converted from 2D structures to 3D 
conformations, and formal charges were assigned to physiological 
conditions (pH = 7.0) The models had their hydrogens optimized, any 
missing side chains were hidden, and the residues Histidine, Proline, 
Asparagine, Glutamine and Cysteine were also optimized. 
4.3. Identification of ligand binding pocket 
The UGT2B17 enzyme have an aglycone binding site, and a co-factor 
binding site, the latter being the focus of this study. Comparison of the 
CT domain crystal structure of human UGT2B7 to other GT family en-
zymes revealed that UDPGA binds to the same site as the co-factor in 
these enzymes. Bacterial enzymes are part of the GT family and use UDP- 
glucose as co-factor substrate, while humans use UDP-glucuronic acid. 
One of the chosen templates, namely the structure of GT OleD (PDB id: 
4M8328) was crystalized in complex with UDP, this indicated the puta-
tive binding site. Interestingly, human UGTs can utilise multiple UDP- 
sugars with diverse glycone moieties, however, UDP-glucuronic acid 
remains the primary co-factor. 
Since UDP lacked the glucuronic acid moiety of UDPGA, the binding 
site determined from UDP by ICM would have been too short and missed 
several residues of importance. This was solved by an initial docking of 
UDPGA in the pocket of Model_2O6L indicated by the superimposed 
UDP, giving an excellent pose and a good score for the docked co-factor. 
This UDPGA pose was later superimposed on all models, and residues in 
the models in a 5 Å vicinity to the superimposed ligand were selected, 
thereby defining the binding pocket to be used in the main docking 
procedure. In the procedure of using UDPGA to define the binding 
pocket, the binding pocket of 2O6L and 4 M83 has been compared to 
confirm the validity of the superimposition of UDPGA with UDP 
(Figure 6). The cofactor binding site of the CT domain are shown in 
Figure 7. 
4.4. Docking of inhibitors and decoys 
Docking of known inhibitors of UGT2B17 and decoys into the pu-
tative binding pocket of the models was carried out to investigate the 
accuracy of the models. A semi-flexible docking approach was used in 
this study. This keeps the ligands fully flexible, and the homology 
models are represented as rigid structures. Protein structure backbone 
and sidechains of enzymes are considered flexible in nature, with an 
approach using a rigid binding pocket in the docking, this flexibility is 
not taken into account. 
The binding pocket used in the docking is visualized as an energy 
grid, with pre-calculated energy maps representing ligand binding in-
teractions such as van der Waals, hydrogen-bonding, electrostatics, and 
hydrophobic interactions. The box defining the energy grid maps was set 
to include the entire binding pocket, and to exclude neighboring cavities 
Figure 7. Superimposition of all four models. Color coding: 4 M83 (pink), 2O6L (yellow), 3WAD (orange), AMG (green). (For interpretation of the references to color 
in this figure legend, the reader is referred to the web version of this article.) 
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Figure 8. Homology models and their corresponding Ramachandran Plot. The models are visualized as ribbons, with the protein chain colour scheme of a rainbow, 
from blue at the amino-terminus to red at the carboxy-terminus. The Ramachandran Plot was generated by ProCheck, showing residues in the most favoured regions 
(red), additionally allowed regions (yellow), generously allowed regions (beige) and disallowed regions (white). (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
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which could disturb the docking. The ligand binding probe in the 
binding pocket was kept at default, as predicted by ICM using the Monte 
Carlo global optimization procedure. 
The chemical table of inhibitors and decoys was docked into the 
binding pocket using the docking macro of ICM. Three parallel dockings 
runs were done on all four models. Once the docking was finished, a 
collection of the most energetically favorable poses of the ligands were 
collected and could be displayed interactively inside the binding pocket. 
4.5. Evaluation of docking 
The docking was evaluated using ROC curves, giving insights to the 
overall predictability of the built models. The scores obtained by the 
docking process were analyzed using the inbuilt ROC-curve command in 
ICM. The positives (inhibitors) docked were labelled as 1, while nega-
tives (decoys) were labelled as 0. The results were displayed as ROC 
curves, the AUC was calculated and interpreted. 
5. Results 
The final models, Model_3WAD, Model_4AMG and Model_4M83, and 
Model_2O6L (partial model), are shown in Figures 8 and 9. The partial 
model contained the co-factor binding site, and all full length models 
contained the typical structural characteristics of GTs and UGTs, an NT 
domain with the aglycone binding site, a conserved CT domain with the 
Figure 9. Homology model 2O6L and its corresponding Ramachandran Plot. The model is visualized as ribbon, with the protein chain colour scheme of a rainbow, 
from blue at the amino-terminus to red at the carboxy-terminus. The Ramachandran Plot was generated by ProCheck, showing residues in the most favoured regions 
(red), additionally allowed regions (yellow), generously allowed regions (beige) and disallowed regions (white). (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
Figure 10. Model_3WAD superimposed on templates. Model shown in red, templates in grey. Left panel shows 3WAD template, and right panel shows 2O6L 
template. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
Table 3 










3WAD 83.1% 12.6% 3.6% 0.8% 
4AMG 86.0% 10.8% 2.8% 0.5% 
4 M83 87.5% 11.0% 1.3% 0.3% 
2O6L 94.2% 5.0% 0.7% 0.0%  
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co-factor binding site, and a catalytic cleft between them. 
The Ramachandran plots of the models are displayed in Figures 8 and 
9, and their ProCheck statistics are shown in Table 3. The Ramachan-
dran plot visualizes the stereo chemical quality of the models, and their 
overall and residue-by-residue geometry. 
The evaluation of models the WhatCheck tool, which did extensive 
checking of many stereochemical parameters of the residues in the 
models, showed that all models passed the overall summary rapport, 
confirming that the models were of satisfactory quality. In conclusion, 
Model_2O6L was of good quality, the others were of acceptable 
quality.17,12 
Figures 10-13 show the models superimposed on their UGT template 
for investigation of whether the CT domain of models resemble their 
template. The calculated RMSDs of the models’ backbone Cα (CT 
domain and the binding pocket) are shown in Table 4. The RMSD de-
scribes the degree of similarity between superimposed structures, and 
RMSD values are presented in Ångstrom (Å). Low RMSD values below 2 
Å means the two structures are similar, while a value of 0 Å implicate 
that two structures are identical in conformation. The structures of the 
models were relatively conserved on the CT domain template, with 
RMSD values ranging from 0.157 Å to 1.759. The binding pockets were 
more conserved, with RMSD values ranging from 0.149 Å to 0.840 Å. 
Enzymes that are part of the GT family share a common co-factor 
binding site located in the CT domain of the protein. Several experi-
mentally determined crystal structures have confirmed this, including 
the templates used in this study. Superimposing the structure of GT OleD 
in complex with UDP on the models indicated the putative binding site. 
An initial docking run of UDPGA in the binding pocket of Model_2O6L 
indicated by the superimposed UDP was performed. This gave the co- 
factor UDPGA an excellent pose and fit in the binding pocket, with a 
good docking score of − 49, as shown in Figure 14. 
A chemical table of 10 inhibitors and 145 decoys were docked in a 
semi-flexible mode into the putative binding site of UGT2B17, to eval-
uate the ability of the homology models to differentiate between them. 
The experimentally determined binding affinities of the inhibitors are 
shown in Table 2. The inhibitors were a diverse set of compounds, with 
different degree of inhibition of the target enzyme. The binding poses of 
the docked inhibitors were investigated, and the score values analyzed. 
Residues of importance for binding of UDPGA are shown as bold in 
Table 5. Most of the inhibitors were docked into the electronegative 
centrum of the pocket, as shown in Figure 15. 
ROC curves were made to evaluate the ability of the models to 
Figure 11. Model_4AMG superimposed on templates. Model shown in green, templates in grey. Left panel shows 4AMG template, and right panel shows 2O6L 
template. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
Figure 12. Model_4M83 superimposed on templates. Model shown in blue, templates in grey. Left panel shows 4 M83 template, and right panel shows 2O6L 
template. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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differentiate between binders (inhibitors) and non-binders (decoys). The 
closer the curve follows the left-hand border and then the top border of 
the ROC space, the more accurate the model. A diagonal curve repre-
sents a model which is not able to discriminate between true positives 
and false positives. The calculated AUC for the ROC curves is a measure 
of the accuracy of the models, shown in percentage. Three parallel 
docking runs were performed for the results to be statistically viable. 
The ROC curves of all docking runs are shown in Figures 14-17, the 
calculated AUCs are shown in Table 6. No relationship was observed 
between docking scores of UGT2B17 inhibitors and their inhibitory ac-
tivities when comparing docking scores and inhibitory activities for each 
of the compounds, but the ROC curves indicated that the models are able 
to discriminate between binders and non-binders. Fig 18. 
Model_3WAD had ROC curves closer to the diagonal than the other, a 
mean AUC value of 73.93, indicating that this model was acceptable at 
differentiating true binders from decoys. Model_4M83 had a mean AUC 
value of 81.93. Model_2O6L had a mean AUC value of 82.61. These 
Figure 14. UDPGA docked into binding pocket of Model_2O6L. The surface of the pocket is coloured by the binding properties. Aromatic lipophilic shown as white. 
Aliphatic lipophilic shown as green, HBA potential shown as red, HBD potential shown as blue. (For interpretation of the references to color in this figure legend, the 
reader is referred to the web version of this article.) 
Figure 13. Model_2O6L superimposed on template. Model shown in yellow, 
template in grey. (For interpretation of the references to color in this figure 
legend, the reader is referred to the web version of this article.) 
Table 5 
Residues forming the co-factor binding site in the models. Residues most likely 
to have contact with ligands are shown as bold.  
Model Residues forming the co-factor binding site 
3WAD E32, Y33, S34, H35, I37, N38, V278, G279, G280, L281, S309, G311, S312, 
M313, R339, K356, W357, L358, P359, Q360, N361, L364, F372, T374, 
H375, G376, G377, T378, N379, G380, I381, E383, F397, A398, D399, 
Q400, N403 
4AMG E32, Y33, S34, V278, K284, S309, G311, S312, M313, R339, K356, W357, 
L358, P359, Q360, N361, L364, F372, T374, H375, G376, G377, T378, 
N379, G380, I381, E383, F397, A398, D399, Q400, N403 
4 M83 D88, F90, M93, H282, K284, S309, G311, S312, M313, R339, K356, W357, 
L358, P359, Q360, N361, L364, T374, H375, G376, G377, T378, N379, 
G380, I381, Y382, E383, F397, A398, D399, Q400, N403 
2O6L S309, G311, S312, M313, R339, K356, W357, L358, P359, Q360, N361, 
L364, F372, T374, H375, G376, G377, T378, N379, G380, I381, E383, 
F397, A398, D399, Q400, N403  
Table 4 
Calculated root-meansquare-deviation for the models.  
Model RMSD for the CT domain RMSD for the binding pocket 
3WAD 1.264 Å 0.445 Å 
4AMG 1.759 Å 0.840 Å 
4 M83 1.184 Å 0.685 Å 
2O6L 0.157 Å 0.149 Å  
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models had higher AUCs, but had ROC curves crossing the diagonal line. 
Model_4AMG had ROC curves furthest away from the diagonal line 
curve and never crossing it. This model had the highest calculated AUC 
of 86.09, and mean AUC value was 84.68, which was the highest mean 
value of the models. In conclusion, Model_4AMG was the most accurate 
in distinguishing between true binders and non-binders. Fig 19. 
6. Discussion 
The multiple sequence alignment with the templates used in the 
present study, combined with several other human UGTs, were about 
130 residues shorter than the target. Furthermore, they had low 
sequence identity with target, leading to a difficult alignment process. 
The membrane interacting region in the NT domain added extra 
complexity, since the GT templates lacked this region. This resulted in 
several gaps in the alignments, and these gaps were shifted to the loop 
regions of the alignment if possible. A few site-directed mutagenesis 
studies were available mutagenesis,25,26,29,23 and these aided in the 
alignment process by highlighting regions of importance. The sequence 
identities for the adjusted alignments were 82% for UGT2B7, 20% for GT 
VinC, 22% for GT SnogD, and 21% for GT OleD, as shown in Table 1. 
The sequence identity between target and template strongly corre-
lates with model accuracy, and three of the alignments had a low 
sequence identity. Because of the low sequence identity between GT 
templates and the target, a multi template model procedure was per-
formed. After an initial construction of models based solely on their GT 
template, the partial structure of UGT2B7 was added as a second tem-
plate for the CT domain, improving the quality of the models in this 
region. To be able to utilize homology models for VLS, a sequence 
identity above 60% would be preferred. By combining two templates, 
the overall sequence identity was raised to approximately 55% for the 
three full length models. 
In Ramachandran plots, a good quality model is expected to have 
over 90% of the residues within the most favored regions. According to 
the Ramachandran plots, Model_2O6L was within the threshold of a 
good quality model with a percentage of 94.2% The other models had 
83.1% 86.0% and 87.5% respectively, which is just below the limit for 
good quality models. Of the residues making up the presumed co-factor 
binding pocket, none were in the disallowed regions, and only A398 was 
in the generously allowed region. 
The uncertainty in these models were most profound in the NT do-
mains, due to gaps in the alignments and low sequence identity. This 
resulted in substantial structural differences, with some long secondary 
structures pointing out of the NT domain of the models. Model_4AMG 
had two long helices pointing outwards, while the other models had a 
few extra loop regions. The models superimposed on their correspond-
ing GT templates are shown to the left in Figures 10-13. Since the co- 
factor binding site built up by the CT domain, and some residues in 
the core of the NT domain, were the main areas of interest in this study, 
the uncertainty in the peripheral secondary structures of the NT domain 
were of less importance. 
When the four models were superimposed, as shown in Figure 20, the 
structural differences and similarities of the models became evident. The 
NT domain of the templates were highly variable, resulting in very 
different models. The CT domains were highly conserved in all the 
templates, and adding a second template for this region made the 
structural similarity even better. 
Some of the residues from the site-directed mutagenesis studies were 
conserved in the models, as seen in the alignments. The two residues 
involved in the catalytic reaction of the enzyme (H35 and D152) were 
positioned close to the UDPGA binding site in the core of all the models, 
as needed to initiate the catalysis, as shown in Figure 21. The residue 
F90 responsible for ring stacking interactions with the aglycone was also 
in close proximity in Model_4AMG and Model_4M83. These conserved 
residues at key positions increased the possibility that the built models 
were similar to the target in the core region of the enzymes, despite the 
relatively low sequence identity in the NT domain. 
This UDPGA pose was superimposed on all models, and residues in a 
5 Å vicinity to the superimposed UDPGA ligand were selected, thereby 
defining the binding pocket to be used in the docking process. Mod-
el_3WAD, Model_4AMG, Model_4M83 and Model_2O6L had 37, 32, 33 
and 27 residues defining the binding pocket, respectively. Model_3WAD 
had the linker region between the two domains in close vicinity to the 
co-factor binding pocket, adding extra residues and narrowing the 
pocket. Table 5 lists all residues forming the binding pocket of the 
models. 
Comparing several crystal structures of GTs in complex with ligand 
(including GT OleD) with crystal structures without a ligand, have 
Figure 15. Model_4AMG shown as electrostatic potential. Areas coloured blue represent positive areas, red represents negative areas, and white represents neutral 
areas. The ten docked inhibitors shown in binding pocket. UDPGA added as reference, shown in green. (For interpretation of the references to color in this figure 
legend, the reader is referred to the web version of this article.) 
I. Trane et al.                                                                                                                                                                                                                                    
Bioorganic & Medicinal Chemistry 36 (2021) 116060
15
shown a conformational change of W357, moving the residue closer to 
the ligand. The conformational change, presumably initiated by co- 
factor binding, could make aromatic ring stacking interactions 
possible between the aromatic ring of W357 and the uracil of UDPGA. 
This conformational change makes the residue important for ligand 
binding, despite its initial peripheral placement in the binding 
pocket24,20. 
Figure 22 shows Compound 2 and its putative binding interactions 
with the binding pocket. Hydrophobic interactions were observed with 
Y33, L63, H375, G377, T378, and N379. One of the aromatic rings of 
Compound 2 could participate in stacking interactions with Y33. 
Hydrogen bonds were observed to S34, S312, D399 and Q400, the dis-
tance being 2.9 Å, 2.4 Å, 3.2 Å and 2.5 Å respectively. There was also a 
possibility that hydrogen bonds could also be formed with residues 
Q360, T378 and N379. 
The crystal structure of UGT2B7 shows the presence of water 
Figure 17. ROC curves for 3 parallel dockings on Model_4AMG. True positive 
rate on y-axis, false positive rate on x-axis. 
Figure 16. ROC curves for 3 parallel dockings on Model_3WAD. True positive 
rate on y-axis, false positive rate on x-axis. 
Table 6 
Calculated AUC for all docking runs.  
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molecules in the binding pocket, suggesting that some of these could be 
involved in hydrogen bond interactions between ligands and the pro-
tein. The presence of water in the pocket was not accounted for in the 
docking process, but when superimposing the water molecules of the 
UGT2B7 template on Model_4AMG, water mediated interactions were 
possible with R339 and T374. 
The ligand binding interactions described are not as static as the 
figures shows. In reality, both the enzyme and the ligand have natural 
structural flexibility and motion, making it easier to interact with resi-
dues in the binding pocket. The presumed conformational change upon 
ligand binding may also affect the binding pocket interactions. These 
figures are snapshots of how the ligand–protein complex could appear in 
reality. 
Site directed mutagenesis studies were available for other 
UGTs.25,26,29,23 These confirmed that residues S34, S309, R339, W357, 
Q360, E373, T374, H375, N379, G380, E383, D399 and Q400, 
positioned in the binding pocket, were involved in co-factor binding. 
Several of these residues were involved in binding interactions with 
compound 2, confirming the putative binding site in models. This study 
has shown that residues Y33, L63, S312, G377, and T378 may also be 
involved in ligand binding interactions. These residues along with the 
other NT domain residues listed in Table 5 could be interesting to study 
further in future site-directed mutagenesis studies. If experimental 
studies through crystal structures or site-directed mutagenesis studies 
could confirm these residues as important, it would be possible to 
conclude that the models were partially correct, and that the proposed 
residues were involved in ligand binding.25,20 
Model_4AMG was, according to the ROC curves, better at discrimi-
nating between binders from decoys than Model_2O6L, despite the 
lower sequence identity and RMSD of binding pocket. This indicates that 
the NT domain residues of Model_4AMG could be important for ligand 
binding. 
Figure 19. ROC curves for 3 parallel dockings on Model_2O6L. True positive 
rate on y-axis, false positive rate on x-axis. 
Figure 18. ROC curves for 3 parallel dockings on Model_4M83. True positive 
rate on y-axis, false positive rate on x-axis. 
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A poor value from the calculated AUC can indicate that a model is 
unable to distinguish between decoys and inhibitors. However, this does 
not necessarily imply that the model is inaccurate. In general, the ROC 
curve depends heavily on the choice of decoys. Decoys for the ROC 
curves were generated by the Decoyfinder software,8 since none were 
available from experimental data. These decoys are compounds with 
similar physiochemical properties and MW, presumed to be inactive. 
Without experimentally determined decoys, some of the theoretical 
decoys could actually be true binders, and may have generated false 
negatives, affecting the TPR in the curves. 
In this study, homology models were constructed as working tools to 
aid in the design of experimental studies related to UGT2B17. Molecular 
docking of known ligands into the putative binding sites of UGT2B17 
models was carried out to explore its overall predictability and aid in 
designing rational inhibitors. Molecular docking is a widespread 
approach for determining protein–ligand interactions, and it is used to 
predict potential ligand binding site of a target protein. Molecular 
studies on the binding sites of UGT2B17 may provide insightful infor-
mation about key interactions and characteristics that may aid in 
designing new drugs. 
Pharmacological UGT2B17 inhibition could provide novel treatment 
for patients with low testosterone levels. Use of currently available 
pharmacological testosterone replacement may have unwanted side ef-
fects. In a study of men aged 65 years or older, increased coronary artery 
plaque volume was found after 1 year of treatment.6 Inability to provide 
patients with a stable elevation of serum testosterone levels, could be 
related to adverse effects. Swerdloff et al. found that transdermal 
testosterone gel application gives a highly variable and unpredictable 
increase in serum concentrations.27 Rather than un-physiological 
elevation of serum levels through direct treatment with testosterone, 
Figure 21. Residues H35 and D152 forming the catalytic dyad, and residue F90 crucial for interactions with the aglycone, all in close proximity to UDPGA situated in 
the binding pocket of Model_4AMG. NT domain shown as ribbon, CT domain shown as mesh. 
Figure 20. The four homology models superimposed. Model_3WAD shown as 
red, Model_4AMG shown as green, Model_4M83 shown as blue, and Mod-
el_2O6L shown as yellow. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
Figure 22. Presumed binding interactions between compound 2 and the 
binding pocket. 
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UGT2B17 inhibition may elevate endogenous testosterone levels and 
provide a more predictable increase in serum concentrations. This could 
be favorable both for giving a predictable treatment regime with a stable 
testosterone substitution and reduce chance for serious adverse effects. 
Coordinates are available upon request. 
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